Movement Alert｜INNOVENT BIO Rises 3.78% in Regular Trading, Strong H1 Performance and New Retail Channel Expansion Fuel Optimism

Market Focus

Aug 17

On August 17, INNOVENT BIO rose 3.78% in regular trading, trading at 97.4 HKD/share, with turnover of HKD 219 million.

The rally was driven by a combination of catalysts: the company recently partnered with Meituan to explore an instant retail model for pharmaceutical products and launched small-specification new products, expanding its commercialization channels. Additionally, the company announced that its board will convene on August 25 to review interim results, heightening market anticipation for the upcoming mid-year report.

The optimism is underpinned by previously disclosed strong financials — first-half product revenue exceeded RMB 8.2 billion, representing over 55% year-over-year growth, with Q2 product revenue surpassing RMB 4.3 billion, up approximately 60% YoY, significantly beating market expectations. Multiple investment banks have reiterated buy ratings, with Goldman Sachs raising its target price to HKD 111.68, BOCOM International setting a target of HKD 118, and Citi reaffirming its target at HKD 115, all citing accelerating commercialization momentum and growing confidence in the company's RMB 20 billion domestic revenue target for next year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1111502666"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1111502666\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1111502666?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-17 10:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111502666","market":"hk","top_or_hot":-1,"title":"Movement Alert｜INNOVENT BIO Rises 3.78% in Regular Trading, Strong H1 Performance and New Retail Channel Expansion Fuel Optimism","media":"Market Focus","content":"<p><p>On August 17, INNOVENT BIO rose 3.78% in regular trading, trading at 97.4 HKD/share, with turnover of HKD 219 million.</p><p>The rally was driven by a combination of catalysts: the company recently partnered with Meituan to explore an instant retail model for pharmaceutical products and launched small-specification new products, expanding its commercialization channels. Additionally, the company announced that its board will convene on August 25 to review interim results, heightening market anticipation for the upcoming mid-year report.</p><p>The optimism is underpinned by previously disclosed strong financials — first-half product revenue exceeded RMB 8.2 billion, representing over 55% year-over-year growth, with Q2 product revenue surpassing RMB 4.3 billion, up approximately 60% YoY, significantly beating market expectations. Multiple investment banks have reiterated buy ratings, with Goldman Sachs raising its target price to HKD 111.68, BOCOM International setting a target of HKD 118, and Citi reaffirming its target at HKD 115, all citing accelerating commercialization momentum and growing confidence in the company's RMB 20 billion domestic revenue target for next year.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜INNOVENT BIO Rises 3.78% in Regular Trading, Strong H1 Performance and New Retail Channel Expansion Fuel Optimism</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜INNOVENT BIO Rises 3.78% in Regular Trading, Strong H1 Performance and New Retail Channel Expansion Fuel Optimism\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-17 10:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 17, INNOVENT BIO rose 3.78% in regular trading, trading at 97.4 HKD/share, with turnover of HKD 219 million.</p><p>The rally was driven by a combination of catalysts: the company recently partnered with Meituan to explore an instant retail model for pharmaceutical products and launched small-specification new products, expanding its commercialization channels. Additionally, the company announced that its board will convene on August 25 to review interim results, heightening market anticipation for the upcoming mid-year report.</p><p>The optimism is underpinned by previously disclosed strong financials — first-half product revenue exceeded RMB 8.2 billion, representing over 55% year-over-year growth, with Q2 product revenue surpassing RMB 4.3 billion, up approximately 60% YoY, significantly beating market expectations. Multiple investment banks have reiterated buy ratings, with Goldman Sachs raising its target price to HKD 111.68, BOCOM International setting a target of HKD 118, and Citi reaffirming its target at HKD 115, all citing accelerating commercialization momentum and growing confidence in the company's RMB 20 billion domestic revenue target for next year.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信达生物","start_time":0,"source_url":"","article_id":"1111502666","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111502666","pubTimestamp":1786932471,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 17, INNOVENT BIO rose 3.78% in regular trading, trading at 97.4 HKD/share, with turnover of HKD 219 million.The rally was driven by a combination of catalysts: the company recently...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01801":"信达生物"},"translate_title":"动态警报|信达生物常规交易上涨3.78%，上半年强劲业绩和新零售渠道扩张引发乐观情绪","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"On August 17, INNOVENT BIO rose 3.78% in regular trading, trading at 97.4 HKD/share, with turnover of HKD 219 million.The rally was driven by a combination of catalysts: the company recently partnered with Meituan to explore an instant retail model for pharmaceutical products and launched small-specification new products, expanding its commercialization channels. Additionally, the company announced that its board will convene on August 25 to review interim results, heightening market anticipation for the upcoming mid-year report.The optimism is underpinned by previously disclosed strong financials — first-half product revenue exceeded RMB 8.2 billion, representing over 55% year-over-year growth, with Q2 product revenue surpassing RMB 4.3 billion, up approximately 60% YoY, significantly beating market expectations. Multiple investment banks have reiterated buy ratings, with Goldman Sachs raising its target price to HKD 111.68, BOCOM International setting a target of HKD 118, and Citi reaffirming its target at HKD 115, all citing accelerating commercialization momentum and growing confidence in the company's RMB 20 billion domestic revenue target for next year.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}